Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study
Menée aux Etats-Unis à partir de données portant sur 688 et 592 patients atteints d'un syndrome myélodysplasique, cette étude évalue l'efficacité, du point de vue de la survie globale, d'une greffe allogénique de cellules souches hématopoïétiques selon la catégorie d'âge du patient (55-64 ans et 65 ans et plus) (durée médiane de suivi : 47 mois)
The median age of patients with myelodysplastic syndromes (MDS) at diagnosis is more than 70 years, and allogeneic hematopoietic stem-cell transplantation (allo-HCT) remains the only potentially curative therapy.1 The introduction of reduced-intensity conditioning regimens has substantially extended the use of allo-HCT to patients aged 65 years or older, but only a small minority of patients in this age group are undergoing this procedure at present. In fact, in a retrospective European Group for Blood and Marrow Transplantation analysis, only 16 patients older than 70 years underwent allo-HCT between 2000 and 2004; however, numbers increased to 181 patients between 2011 and 2013.2 The increase was a result of improved selection criteria for these patients.
JAMA Oncology 2019